When it comes to quality health care, the U.S. Latino population starts out at a serious demographic disadvantage. We are more likely to lack health insurance and face other serious hurdles to accessing quality care. And the incidence of serious disease is much higher among Hispanics than the American population at large.
So it should be considered good news for our community, as well as anyone concerned with public health, that two new drugs for people with very high cholesterol are now available—medicines that reduce cholesterol about twice as much as existing drugs. But an obscure group called the Institute for Clinical and Economic Review, or ICER, is preventing and bogging down access to these types of medicines for patients in need.
Read Full Article »